Edition:
India

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

133.66USD
1:30am IST
Change (% chg)

$-2.09 (-1.54%)
Prev Close
$135.75
Open
$136.50
Day's High
$136.85
Day's Low
$133.24
Volume
150,140
Avg. Vol
182,014
52-wk High
$181.70
52-wk Low
$87.64

Latest Key Developments (Source: Significant Developments)

Bluebird Bio Announces EU Conditional Marketing Authorization For Zynteglo
Monday, 3 Jun 2019 

June 3 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO ANNOUNCES EU CONDITIONAL MARKETING AUTHORIZATION FOR ZYNTEGLO™ (AUTOLOGOUS CD34+ CELLS ENCODING ΒA-T87Q-GLOBIN GENE) GENE THERAPY FOR PATIENTS 12 YEARS AND OLDER WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA WHO DO NOT HAVE Β0/Β0 GENOTYPE.WILL CONTINUE COUNTRY-BY-COUNTRY REIMBURSEMENT PROCESS TO HELP ENSURE ACCESS TO ZYNTEGLO FOR APPROPRIATE PATIENTS.  Full Article

Bluebird Bio QTRLY Net Loss Per Share $2.99
Friday, 3 May 2019 

May 2 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q1 REVENUE $12.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $13.2 MILLION.ENDED QUARTER WITH $1.73 BILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.QTRLY NET LOSS PER SHARE $2.99.Q1 EARNINGS PER SHARE VIEW $-2.80, REVENUE VIEW $13.2 MILLION -- REFINITIV IBES DATA.  Full Article

EU Medicines Agency Panel Recommends Conditional Approval Of Bluebird Bio's Zynteglo
Friday, 29 Mar 2019 

March 29 (Reuters) - European Medicines Agency::EU MEDICINES AGENCY PANEL RECOMMENDS APPROVAL OF BLUEBIRD BIO’S GENE THERAPY ZYNTEGLO FOR TREATMENT OF A TYPE OF BLOOD DISORDER WITH CONDITIONS.  Full Article

Bluebird Bio Reports Fourth Quarter And Full Year 2018 Financial Results And Highlights Operational Progress
Friday, 22 Feb 2019 

Feb 21 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q4 REVENUE $19.2 MILLION VERSUS $4.2 MILLION.Q4 REVENUE ESTIMATE $8.1 MILLION -- REFINITIV IBES DATA.QTRLY LOSS PER SHARE $2.72.Q4 EARNINGS PER SHARE VIEW $-2.86 -- REFINITIV IBES DATA.  Full Article

Bluebird Bio Appoints Chip Baird From Amicus Therapeutics As CFO
Monday, 11 Feb 2019 

Feb 11 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO APPOINTS CHIP BAIRD AS CHIEF FINANCIAL OFFICER.BLUEBIRD BIO INC - JEFF WALSH TO ASSUME ROLE OF CHIEF STRATEGY OFFICER.BLUEBIRD BIO INC - JASON COLE TO ASSUME ROLE OF CHIEF OPERATING AND LEGAL OFFICER.BLUEBIRD BIO INC - BAIRD JOINS BLUEBIRD FROM AMICUS THERAPEUTICS.  Full Article

Bluebird Bio Q3 Revenue $11.5 Million
Friday, 2 Nov 2018 

Nov 1 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q3 REVENUE $11.5 MILLION VERSUS $7.7 MILLION.Q3 REVENUE VIEW $7.5 MILLION -- THOMSON REUTERS I/B/E/S.ENDED QUARTER WITH $2.0 BILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.ANTICIPATES THAT ITS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND OPERATIONS INTO 2022.QTRLY LOSS PER SHARE $2.73.COMPANY PLANS TO PURSUE ACCELERATED DEVELOPMENT PATHWAY FOR LENTIGLOBIN(TM) IN SICKLE CELL DISEASE (SCD).Q3 EARNINGS PER SHARE VIEW $-2.84 -- THOMSON REUTERS I/B/E/S.  Full Article

Bluebird Bio Reports Q4 Loss Per Share $2.52‍​
Thursday, 22 Feb 2018 

Feb 21 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q4 REVENUE $4.2 MILLION VERSUS $1.6 MILLION.‍ENDED YEAR WITH $1.6 BILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES​.QTRLY LOSS PER SHARE $2.52‍​.  Full Article

Bluebird Bio Expects Three Regulatory Filings By End 2019
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO CEO SAYS EXPECTS THREE REGULATORY FILINGS BY END 2019.BLUEBIRD SEES FILING FOR APPROVAL IN BETA THALASSEMIA IN 2018.BLUEBIRD BIO SEES FILING FOR US AND EU APPROVAL OF B2121 FOR MULTIPLE MYELOMA IN 2019.  Full Article

Bluebird Bio Prices Public Offering Of 3.2 Mln Shares At $185/Share
Wednesday, 13 Dec 2017 

Dec 12 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.‍PRICED UNDERWRITTEN PUBLIC OFFERING OF 3.2 MILLION SHARES OF ITS COMMON STOCK AT $185 PER SHARE​.  Full Article

Bluebird Bio Announces Proposed Public Offering Of Common Stock
Tuesday, 12 Dec 2017 

Dec 11 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.BLUEBIRD BIO INC - HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $600 MILLION OF ITS COMMON STOCK.  Full Article

Photo

Bluebird prices gene therapy at 1.58 million euros over 5 years

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.